Kevin Coveney
Director of Finance/CFO at ENVERIC BIOSCIENCES, INC.
Net worth: 86 500 $ as of 2024-03-30
Profile
Kevin M Coveney is the founder of Coveney Capital Advisors LLC, which was founded in 2020.
He held the title of Chief Financial Officer during his time there.
He is currently the Chief Financial Officer at Enveric Biosciences, Inc. since 2023.
In his former positions, Mr. Coveney served as the Chief Financial Officer at Memgen, Inc. from 2021 to 2022.
Prior to that, he was the Senior Vice President-Finance, HR & IT at Vedanta Biosciences, Inc. from 2018 to 2020.
He also served as the Chief Financial Officer at Q-State Biosciences, Inc. from 2020 to 2021.
Before transitioning to the biosciences industry, he worked as an Audit Partner at Braver PC from 2007 to 2012.
Mr. Coveney obtained his undergraduate degree from the University of Massachusetts.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-02-21 | 86,500 ( 1.19% ) | 86 500 $ | 2024-03-30 |
Kevin Coveney active positions
Companies | Position | Start |
---|---|---|
ENVERIC BIOSCIENCES, INC. | Director of Finance/CFO | 2023-03-12 |
Former positions of Kevin Coveney
Companies | Position | End |
---|---|---|
Memgen, Inc.
Memgen, Inc. Pharmaceuticals: MajorHealth Technology Memgen, Inc. operates as a clinical-stage biotech company. Its product ISF35, is a viral cancer immunotherapy encoding an optimized version of CD40 ligand. The company was founded by Robert C. Coates and is headquartered in Houston, TX. | Director of Finance/CFO | 2022-05-31 |
Q-State Biosciences, Inc.
Q-State Biosciences, Inc. BiotechnologyHealth Technology Q-State Biosciences, Inc. operates as Biotechnology Company. It offers cardiology, neurology, toxicity screening, drug discovery, drug efficacy screening, pathology modeling, optogenetic, electrophysiology, voltage and calcium signal. The company was founded by Adam E. Cohen, Kevin Eggan, David Margulies and Joel Kralj and is headquartered in Cambridge, MA. | Director of Finance/CFO | 2021-03-31 |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | Director of Finance/CFO | 2020-01-31 |
Braver PC
Braver PC Miscellaneous Commercial ServicesCommercial Services Part of Marcum Wealth LLC, Braver PC provides accounting services. The private company is based in Newton, MA. Braver was acquired by Marcum LLP, a SUB of Marcum Wealth LLC from The Braver Group on January 13, 2014. | Corporate Officer/Principal | 2012-09-30 |
Training of Kevin Coveney
University of Massachusetts | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ENVERIC BIOSCIENCES, INC. | Health Technology |
Private companies | 4 |
---|---|
Braver PC
Braver PC Miscellaneous Commercial ServicesCommercial Services Part of Marcum Wealth LLC, Braver PC provides accounting services. The private company is based in Newton, MA. Braver was acquired by Marcum LLP, a SUB of Marcum Wealth LLC from The Braver Group on January 13, 2014. | Commercial Services |
Memgen, Inc.
Memgen, Inc. Pharmaceuticals: MajorHealth Technology Memgen, Inc. operates as a clinical-stage biotech company. Its product ISF35, is a viral cancer immunotherapy encoding an optimized version of CD40 ligand. The company was founded by Robert C. Coates and is headquartered in Houston, TX. | Health Technology |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | Health Technology |
Q-State Biosciences, Inc.
Q-State Biosciences, Inc. BiotechnologyHealth Technology Q-State Biosciences, Inc. operates as Biotechnology Company. It offers cardiology, neurology, toxicity screening, drug discovery, drug efficacy screening, pathology modeling, optogenetic, electrophysiology, voltage and calcium signal. The company was founded by Adam E. Cohen, Kevin Eggan, David Margulies and Joel Kralj and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Kevin Coveney